Work

Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

Year: 2019

Type: erratum

Source: Molecular Psychiatry

DOI: 10.1038/s41380-018-0311-2

Authors: Maurizio Fava, Marlene P. Freeman, Martina Flynn, Heidi Judge, Bettina B. Hoeppner, Cristina Cusin, Dawn F. Ionescu, Sanjay J. Mathew, Lee C. Chang, Dan V. Iosifescu, James Murrough, Charles Debattista, Alan F. Schatzberg, Madhukar H. Trivedi, Manish K. Jha, Gerard Sanacora, Samuel T. Wilkinson, George I. Papakostas

Institutions: Massachusetts General Hospital, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Icahn School of Medicine at Mount Sinai, Stanford Medicine, Stanford University, The University of Texas Southwestern Medical Center, Yale University

Language: English

Topic: Treatment of Major Depression

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health, National Institute on Drug Abuse, National Center for Advancing Translational Sciences

Awards: G2169753111, G4726124239, G8248535489, Yale Clinical and Translational Science Award

OpenAlex ID: W2912941190

Cites:

Cited by: 18

Related to: 10